Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (princeps drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Servier clinical operations division is part of the R&D and carries out most of the clinical programs end to end from the feasibility of the studies to the database lock. All key expertise in the field of clinical operations are represented in house including data experts, logistics experts, field and project management experts. A dedicated patient In Correspondant working on patient experience is being developed.
The program involves the necessity of building clinical operations strategy adapted to complex multi-sponsor trials in which Servier can contribute.
Servier participates to the following projects which can be connected to EU-PEARL: EHDEN, C4C, PARADIGM.